Thalassemia pathology for neet pg 2026 visual aod
thalassemia pathology types alpha beta molecular defects hemolysis ineffective erythropoiesis
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 2927
thalassemia pathology diagram blood smear target cells ineffective erythropoiesis

Hugging Face pmc clinical VQA raw
Page 0

| Feature | β-Thalassemia | α-Thalassemia |
|---|---|---|
| Gene affected | β-globin gene (chr 11) | α-globin gene (chr 16) |
| Mutation type | Predominantly point mutations | Predominantly deletions |
| Excess chain | α-chains accumulate | β, γ, δ-chains accumulate |
| Tetramers formed | α₄ (Heinz bodies) | β₄ (HbH), γ₄ (Hb Barts) |
| O₂ affinity of tetramers | N/A (precipitate) | Very HIGH — do not deliver O₂ |
Severe Anemia
↓
Marrow Expansion (erythroid hyperplasia)
↓
┌──────────────────────────┬──────────────────────────┐
│ Skeletal Changes │ Extramedullary │
│ • "Hair on end" │ Hematopoiesis │
│ skull X-ray │ • Hepatosplenomegaly │
│ • Crew-cut appearance │ • Paraspinal masses │
│ • Frontal bossing │ │
│ • Rodent facies │ │
└──────────────────────────┴──────────────────────────┘
↓
Iron Overload (↑ GI absorption + transfusions)
↓
Hemosiderosis → Liver cirrhosis, Dilated CMP,
Diabetes, Hypogonadism
| Mediator | Role |
|---|---|
| ERFE (Erythroferrone) | ↑ in ineffective erythropoiesis → ↓ Hepcidin |
| Hepcidin | ↓ → ↑ Ferroportin activity → ↑ GI iron absorption |
| TfR1 (Transferrin Receptor 1) | ↑ on erythroblasts → increased iron uptake |
NEET PG Key Point: Ineffective erythropoiesis → ↑ ERFE → ↓ Hepcidin → Iron overload. This is independent of transfusions.
| Genotype | Alleles deleted | Clinical Picture |
|---|---|---|
| Silent carrier | -α/αα (1 deleted) | Normal, asymptomatic |
| α-Thal trait | --/αα or -α/-α (2 deleted) | Mild microcytic anemia |
| HbH disease | --/-α (3 deleted) | Moderately severe hemolytic anemia, HbH (β₄ tetramers) |
| Hb Barts (Hydrops fetalis) | --/-- (4 deleted) | Incompatible with life, γ₄ tetramers, severe tissue hypoxia |
HbH inclusions stain with brilliant cresyl blue — "golf ball" cells
| Type | Genotype | Hb level | Transfusion |
|---|---|---|---|
| Thalassemia Minor (Trait) | β/β⁺ or β/β⁰ | 9–11 g/dL | Not required |
| Thalassemia Intermedia | β⁺/β⁺ | 6–9 g/dL | Occasional |
| Thalassemia Major (Cooley's anemia) | β⁰/β⁰ | <6 g/dL | Regular transfusions |
| Condition | HbA | HbA2 | HbF |
|---|---|---|---|
| Normal | 97% | 2.5% | <1% |
| β-Thal Minor | ↓ | ↑ (>3.5%) ⭐ | ↑ slightly |
| β-Thal Major | Absent/↓↓ | ↑ | ↑↑ (up to 90%) |
| α-Thal trait | ↓ | Normal/↓ | Normal |
| HbH disease | ↓ | ↓ | Normal + HbH |
NEET PG Key: HbA2 >3.5% = hallmark of β-thalassemia trait. Used for carrier screening.
| System | Complication |
|---|---|
| Cardiac | Dilated cardiomyopathy (iron) — #1 cause of death |
| Liver | Cirrhosis, hepatocellular carcinoma |
| Endocrine | Diabetes, hypogonadism, hypothyroidism, short stature |
| Bone | Osteoporosis, pathological fractures |
| Immune | Asplenia (post-splenectomy) → encapsulated organisms |
| Treatment | Details |
|---|---|
| Regular blood transfusion | Target Hb >10 g/dL; monthly |
| Iron chelation | Desferrioxamine (IV/SC), Deferasirox (oral), Deferiprone (oral) |
| Splenectomy | Reduces transfusion requirement; risk of sepsis |
| Hydroxyurea | ↑ HbF production (β-thal intermedia) |
| Luspatercept | Anti-GDF11 → ↓ ineffective erythropoiesis (newer drug) |
| HSCT (Bone Marrow Transplant) | Only curative option |
| Gene therapy | Betibeglogene (Zynteglo) — approved for β-thalassemia |